Service Cerashield Endotracheal Tube
The Cerashield biofilm resistant endotracheal tube is designed to reduce potentially lethal respiratory infections among mechanically ventilated ICU patients.
The main advantage of the Cerashield endotracheal tube is that it is able to reduce or prevent fouling of the device, which is a key factor in the development of potentially lethal respiratory infections. FDA has designated the device as a “breakthrough device” and it is approved for use in Canada, Brazil, and Colombia. We will be seeking CE mark next year.
- Infection prevention
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Marketed product
- Research
- Development
- Validation
- Market entry
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
Looking for companies with a history of developing and commercializing innovative products with a prominent market position. We are open to field of use licensing, geographic rights, and outright sale for certain applications.
Corporation
Our Cerashield ETT is one of many medical devices that we are developing with the same platform technology. We are currently working on coating orthopedic implants, pacemaker envelope, vascular access (PICC lines) and hemodialysis catheters. Any medical device that is in contact with the patient for more than 4 hours is at risk of developing antibiotic resistant biofilms on its surfaces.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!